Shijiazhuang Lonzeal Pharmaceutical is a company with a full industrial chain of intermediates, APIs and Formulations. The registered capital is RMB85.6 million, covering an area of ​​100,000 square meters and the total assets are RMB600 million. Lonzeal is fully capable of R&D registration, industrial manufacturing, marketing and quality management.International Market: available with USFDA approval, WHO PQ and EU EMA certification, export APIs worldwide, mainly focusing on ARV molecules. Domestic Market:relying on China national centralized procurement policy, making use of the competitive advantages from full industry chain to ensure that varieties win the bids, and expand market size for each single product. Lamivudine API and Tenofovir Disoproxil Fumarate API have both been ce..